vs
Assertio Holdings, Inc.（ASRT）与TRANSACT TECHNOLOGIES INC（TACT）财务数据对比。点击上方公司名可切换其他公司
Assertio Holdings, Inc.的季度营收约是TRANSACT TECHNOLOGIES INC的1.2倍（$13.5M vs $11.5M），TRANSACT TECHNOLOGIES INC同比增速更快（11.9% vs -57.9%），过去两年TRANSACT TECHNOLOGIES INC的营收复合增速更高（3.5% vs -35.4%）
Assertio Therapeutics是一家美国专业制药企业，主要聚焦神经病学、疼痛以及中枢神经系统疾病领域的产品销售与推广。公司前身Depomed成立于1995年，总部位于加利福尼亚州纽瓦克，拥有多款获美国FDA批准的产品，目前在纳斯达克上市。
该公司相关归属主体罗珀技术公司是一家控股集团，主要投资控股科技领域的各类企业，业务覆盖多个科技细分赛道，依托旗下子公司开展多元化科技业务布局。
ASRT vs TACT — 直观对比
营收规模更大
ASRT
是对方的1.2倍
$11.5M
营收增速更快
TACT
高出69.9%
-57.9%
两年增速更快
TACT
近两年复合增速
-35.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $13.5M | $11.5M |
| 净利润 | — | — |
| 毛利率 | — | 47.6% |
| 营业利润率 | -86.7% | -10.1% |
| 净利率 | — | — |
| 营收同比 | -57.9% | 11.9% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-4.54 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASRTTACT
| Q4 25 | $13.5M | $11.5M | ||
| Q3 25 | $49.5M | $13.2M | ||
| Q2 25 | $29.2M | $13.8M | ||
| Q1 25 | $26.5M | $13.1M | ||
| Q4 24 | $32.2M | $10.2M | ||
| Q3 24 | $29.2M | $10.9M | ||
| Q2 24 | $31.1M | $11.6M | ||
| Q1 24 | $32.4M | $10.7M |
净利润ASRTTACT
| Q4 25 | — | — | ||
| Q3 25 | $11.4M | $15.0K | ||
| Q2 25 | $-16.4M | $-143.0K | ||
| Q1 25 | $-13.5M | $19.0K | ||
| Q4 24 | — | — | ||
| Q3 24 | $-2.9M | $-551.0K | ||
| Q2 24 | $-3.7M | $-319.0K | ||
| Q1 24 | $-4.5M | $-1.0M |
毛利率ASRTTACT
| Q4 25 | — | 47.6% | ||
| Q3 25 | — | 49.8% | ||
| Q2 25 | — | 48.2% | ||
| Q1 25 | — | 48.7% | ||
| Q4 24 | — | 44.2% | ||
| Q3 24 | — | 48.1% | ||
| Q2 24 | — | 52.7% | ||
| Q1 24 | — | 52.6% |
营业利润率ASRTTACT
| Q4 25 | -86.7% | -10.1% | ||
| Q3 25 | 23.2% | 0.1% | ||
| Q2 25 | -27.5% | -1.9% | ||
| Q1 25 | -50.0% | -0.1% | ||
| Q4 24 | -41.9% | -10.3% | ||
| Q3 24 | -10.4% | -7.7% | ||
| Q2 24 | -11.6% | -3.8% | ||
| Q1 24 | -13.4% | -12.2% |
净利率ASRTTACT
| Q4 25 | — | — | ||
| Q3 25 | 23.1% | 0.1% | ||
| Q2 25 | -56.0% | -1.0% | ||
| Q1 25 | -51.1% | 0.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | -10.0% | -5.1% | ||
| Q2 24 | -11.8% | -2.8% | ||
| Q1 24 | -13.9% | -9.7% |
每股收益（稀释后）ASRTTACT
| Q4 25 | $-4.54 | $-0.11 | ||
| Q3 25 | $0.11 | $0.00 | ||
| Q2 25 | $-0.17 | $-0.01 | ||
| Q1 25 | $-0.14 | $0.00 | ||
| Q4 24 | $-3.28 | $-0.80 | ||
| Q3 24 | $-0.03 | $-0.06 | ||
| Q2 24 | $-0.04 | $-0.03 | ||
| Q1 24 | $-0.05 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $63.4M | $20.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $94.0M | $31.1M |
| 总资产 | $267.0M | $44.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASRTTACT
| Q4 25 | $63.4M | $20.4M | ||
| Q3 25 | $93.4M | $20.0M | ||
| Q2 25 | $98.2M | $17.7M | ||
| Q1 25 | $87.3M | $14.2M | ||
| Q4 24 | $100.1M | $14.4M | ||
| Q3 24 | $88.6M | $11.3M | ||
| Q2 24 | $88.4M | $11.1M | ||
| Q1 24 | $80.7M | $10.6M |
总债务ASRTTACT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $38.6M | — |
股东权益ASRTTACT
| Q4 25 | $94.0M | $31.1M | ||
| Q3 25 | $105.8M | $31.8M | ||
| Q2 25 | $93.3M | $31.3M | ||
| Q1 25 | $108.5M | $30.9M | ||
| Q4 24 | $121.1M | $30.6M | ||
| Q3 24 | $130.5M | $38.4M | ||
| Q2 24 | $132.2M | $38.5M | ||
| Q1 24 | $134.5M | $38.6M |
总资产ASRTTACT
| Q4 25 | $267.0M | $44.8M | ||
| Q3 25 | $319.8M | $45.0M | ||
| Q2 25 | $273.8M | $44.5M | ||
| Q1 25 | $286.4M | $44.2M | ||
| Q4 24 | $284.7M | $44.0M | ||
| Q3 24 | $276.0M | $50.5M | ||
| Q2 24 | $279.4M | $50.4M | ||
| Q1 24 | $282.0M | $51.9M |
负债/权益比ASRTTACT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.29× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-30.0M | $609.0K |
| 自由现金流经营现金流 - 资本支出 | — | $589.0K |
| 自由现金流率自由现金流/营收 | — | 5.1% |
| 资本支出强度资本支出/营收 | — | 0.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $7.6M |
8季度趋势，按日历期对齐
经营现金流ASRTTACT
| Q4 25 | $-30.0M | $609.0K | ||
| Q3 25 | $-4.8M | $3.6M | ||
| Q2 25 | $19.1M | $3.6M | ||
| Q1 25 | $-12.5M | $-161.0K | ||
| Q4 24 | $11.5M | $2.4M | ||
| Q3 24 | $-35.0K | $327.0K | ||
| Q2 24 | $7.4M | $636.0K | ||
| Q1 24 | $7.5M | $-1.5M |
自由现金流ASRTTACT
| Q4 25 | — | $589.0K | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | — | $3.6M | ||
| Q1 25 | — | $-171.0K | ||
| Q4 24 | — | $2.4M | ||
| Q3 24 | — | $259.0K | ||
| Q2 24 | — | $499.0K | ||
| Q1 24 | — | $-1.6M |
自由现金流率ASRTTACT
| Q4 25 | — | 5.1% | ||
| Q3 25 | — | 27.1% | ||
| Q2 25 | — | 25.9% | ||
| Q1 25 | — | -1.3% | ||
| Q4 24 | — | 23.2% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 4.3% | ||
| Q1 24 | — | -14.9% |
资本支出强度ASRTTACT
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.5% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | 0.0% | 0.6% | ||
| Q2 24 | — | 1.2% | ||
| Q1 24 | — | 1.0% |
现金转化率ASRTTACT
| Q4 25 | — | — | ||
| Q3 25 | -0.42× | 242.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -8.47× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASRT
| Products | $12.8M | 95% |
| Other | $719.0K | 5% |
TACT
暂无分部数据
